Hence, targeting the bCSCs in any subtype, such as luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)-enriched, and triple-negative (TNBC), is the key strategy to conquer therapeutic resistance in BC. This evidence concerns the gene ERBB2 and breast cancer.